FHTX
LLY
The breakup nobody wanted
Eli Lilly’s collaboration with Foghorn Therapeutics is over, and FHTX stock is still sliding like it just heard the words “we need to talk.” The market hates this kind of ending because collaborations aren’t just science; they’re also a signal that a bigger, better-funded partner was willing to keep the relationship going.
Why you should care
When a heavyweight like Lilly walks away, it can feel like the biotech version of getting ghosted by the prom king. The science may still exist, but the cash, validation, and future optionality suddenly look a lot thinner. Add in Wedbush slicing its target by 80%, and you’ve got a double whammy: fewer hopes, less hype.
What this means for the tape
This is the sort of news that can hit a small-cap biotech harder than a failed lab experiment. The collaboration ending doesn’t just remove a potential catalyst — it also raises the usual questions:
- How much value was tied to Lilly staying involved?
- Does Foghorn need to replace that partner fast?
- Is Wall Street now resetting expectations from “maybe moonshot” to “show me the data”?
Big picture: in biotech, a partnership can be a life raft or a neon sign. When the life raft drifts away, the stock usually notices.